A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety and efficacy of controlled-release ropinirole (CR) (1-24mg) administered once daily for 12 weeks in subjects with fibromyalgia.

GlaxoSmithKline Research & Development Ltd.0 sites160 target enrollmentNovember 30, 2004

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Not specified
Sponsor: GlaxoSmithKline Research & Development Ltd.
Enrollment: 160
Status: Active, not recruiting
Last Updated: 13 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

November 30, 2004

End Date

TBD

Last Updated

13 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

GlaxoSmithKline Research & Development Ltd.

Eligibility Criteria

Inclusion Criteria

•A subject will be eligible for inclusion in this study only if all of the following criteria apply:
•1\. Subject is a male or female outpatient, at least 18 years of age.
•A female is eligible to enter and participate in the study if she is of:
•a Non\-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post\-menopausal); or,
•b Childbearing potential, has a negative result on all required pregnancy tests prior to randomization, and agrees to an acceptable contraceptive method as defined in the protocol.
•2\. Subject has a diagnosis of fibromyalgia as confirmed by the American College of Rheumatology (ACR) criteria.
•3\. Subject has baseline PI\-NRS score averaging greater than or equal to 4 during the week prior to randomization (Baseline Period) and at least four pain intensity observations are recorded during the 7 days of the Baseline Period.
•4\. Subject is considered clinically appropriate for therapy with ropinirole based upon the Investigator’s overall clinical evaluation.
•5\. Subject is in good general health apart from fibromyalgia, as determined by the Investigator (based upon the physical and laboratory examinations, ECG and medical history).
•6\. Subject is able to comprehend the study procedures and schedule and is able to comply with study requirements.

Exclusion Criteria

•A subject will not be eligible for inclusion in this study if any of the following criteria apply:
•1\. Other chronic pain condition(s) not associated with FMS.
•2\. Unable to discontinue prohibited medications administered for the relief of pain of FMS or for depression and known to induce drowsiness for the required washout period and throughout the study.
•3\. Subject has had non\-drug therapies for fibromyalgia (such as herbal or holistic medications) or any other special procedures for fibromyalgia (e.g. TENS, acupuncture) within two weeks prior to the time of randomisation or will not be able to forgo these therapies/procedures during the study. Stable exercise regimens may be continued if subjects have been on them for at least 2 weeks prior to the randomisation.
•4\. Known history of hypersensitivity or intolerance to acetaminophen/paracetamol.
•5\. Withdrawal, introduction, or change in dose of HRT and/or any drug known to substantially inhibit CYP1A2 (e.g., ciprofloxacin, cimetidine, Hormone Replacement Therapy) or induce CYP1A2 (e.g. tobacco, omeprazole) within 7 days prior to enrolment.
•6\. Taking any medication with the potential for pharmacokinetic interaction with ropinirole.
•7\. Prior exposure to ropinirole during a previous clinical trial for any indication.
•8\. Presence, or history within the previous 3 months, of significant and/or uncontrolled psychiatric, hematological, renal, hepatic, endocrinological, neurological (other than FMS), or cardiovascular disease or active malignancy (other than basal cell cancer)
•9\. Any abnormality, at Screening, that the investigator deems to be clinically relevant on history, physical examination and in diagnostic laboratory tests including ECG.